文献速递白血病

接受低强度治疗的老年急性髓系白血病患者的老年评估:CALGB 361101报告

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.
PubMed 文献 · Blood Adv · 2022-01-01

CALGB 361101是一项多中心试验的伴随研究,评估老年评估(GA)对接受低强度治疗的≥60岁不适合强化疗的急性髓系白血病(AML)患者生存的预测价值。96例患者入组,基线合并症指数>3、认知评分>4和较低的全球生活质量评分与较短总生存显著相关。工具性日常生活活动依赖和认知障碍与6个月死亡率相关。

要点

  • 基线合并症指数>3、认知评分>4和较低全球生活质量与较短总生存显著相关。
  • 工具性日常生活活动依赖与6个月死亡率相关(HR 3.5)。
  • 认知障碍与6个月死亡率相关(HR 3.1)。

核心结论

  • 评估合并症、认知和自我报告功能的GA指标与生存相关,可作为拟接受低强度AML治疗的老年患者筛查的候选指标。

研究设计与样本

  • CALGB 361101是随机2期试验CALGB 11002的伴随研究,纳入≥60岁且被判定为不适合强化疗的成人患者。
  • CALGB 11002共入组165例患者,其中96例(52%)同时入组361101,中位年龄73.9岁。
  • 在361101中,治疗前及之后每隔一个周期进行GA和生活质量(QOL)评估。
  • 采用Kaplan-Meier估计和Cox比例风险模型评估基线GA和QOL指标与生存的关系。

主要发现

  • 85.4%的参与者完成了至少1次基线评估。
  • 多变量分析中,基线合并症较多(造血细胞移植特异性合并症指数>3)、认知较差(Blessed定向-记忆-集中力评分>4)和较低的欧洲癌症研究与治疗组织全球QOL评分与较短总生存显著相关(每项P<.05),校正Karnofsky体能状态、年龄和治疗组后。
  • 工具性日常生活活动依赖与6个月死亡率相关(HR 3.5;CI 1.2-10.4)。
  • 认知障碍与6个月死亡率相关(HR 3.1;CI 1.1-8.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Geriatric assessment (GA) predicts survival among older adults with acute myeloid leukemia (AML) treated intensively. We evaluated the predictive utility of GA among older adults treated with low-intensity therapy on a multisite trial. We conducted a companion study (CALGB 361101) to a randomized phase 2 trial (CALGB 11002) of adults ≥60 years and considered "unfit" for intensive therapy, testing the efficacy of adding bortezomib to decitabine therapy. On 361101, GA and quality of life (QOL) assessment was administered prior to treatment and every other subsequent cycle. Relationships between baseline GA and QOL measures with survival were evaluated using Kaplan-Meier estimation and Cox proportional hazards models. One-hundred sixty-five patients enrolled in CALGB 11002, and 96 (52%) of them also enrolled in 361101 (median age, 73.9 years). Among participants, 85.4% completed ≥1 baseline assessment. In multivariate analyses, greater comorbidity (hematopoietic cell transplantation-specific comorbidity index >3), worse cognition (Blessed Orientation-Memory-Concentration score >4), and lower European Organization for Research and Treatment of Cancer global QOL scores at baseline were significantly associated with shorter overall survival (P < .05 each) after adjustment for Karnofsky Performance Status, age, and treatment arm. Dependence in instrumental activities of daily living and cognitive impairment were associated with 6-month mortality (hazard ratio [HR], 3.5; confidence interval [CI], 1.2-10.4; and HR, 3.1; CI, 1.1-8.6, respectively). GA measures evaluating comorbidity, cognition, and self-reported function were associated with survival and represent candidate measures for screening older adults planned to receive lower-intensity AML therapies. This trial was registered at www.clinicaltrials.gov as #NCT01420926 (CALGB 11002).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ritchie EK, Klepin HD, Storrick E, et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022. PMID: 35420672. doi:10.1182/bloodadvances.2021006872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。